Literature DB >> 32298876

Dihydrofolate reductase inhibitors for use as antimicrobial agents.

Juan He1, Wenliang Qiao2, Qi An1, Tao Yang3, Youfu Luo4.   

Abstract

Drug-resistant bacteria pose an increasingly serious threat to mankind all over the world. However, the currently available clinical treatments do not meet the urgent demand.Therefore, it is desirable to find new targets and inhibitors to overcome the problems of antibiotic resistance. Dihydrofolate reductase (DHFR) is an important enzyme required to maintain bacterial growth, and hence inhibitors of DHFR have been proven as effective agents for treating bacterial infections. This review provides insights into the recent discovery of antimicrobial agents targeting DHFR. In particular, three pathogens, Escherichia coli (E. coli), Mycobacterium tuberculosis(Mtb) and Staphylococcus aureus(S. aureus), and research strategies are emphasized. DHFR inhibitors are expected to be good alternatives to fight bacterial infections.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bacterial infections; DHFR; Escherichia coli; Mycobacterium tuberculosis; Staphylococcus aureus

Mesh:

Substances:

Year:  2020        PMID: 32298876     DOI: 10.1016/j.ejmech.2020.112268

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Sulfaguanidine Hybrid with Some New Pyridine-2-One Derivatives: Design, Synthesis, and Antimicrobial Activity against Multidrug-Resistant Bacteria as Dual DNA Gyrase and DHFR Inhibitors.

Authors:  Ahmed Ragab; Sawsan A Fouad; Ola A Abu Ali; Entsar M Ahmed; Abeer M Ali; Ahmed A Askar; Yousry A Ammar
Journal:  Antibiotics (Basel)       Date:  2021-02-05

2.  Dihydrofolate Reductase Inhibitors: The Pharmacophore as a Guide for Co-Crystal Screening.

Authors:  João A Baptista; Mário T S Rosado; Ricardo A E Castro; António O L Évora; Teresa M R Maria; Manuela Ramos Silva; João Canotilho; M Ermelinda S Eusébio
Journal:  Molecules       Date:  2021-11-06       Impact factor: 4.411

3.  Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F420H2-dependent reduction.

Authors:  Wassihun Wedajo Aragaw; Brendon M Lee; Xuan Yang; Matthew D Zimmerman; Martin Gengenbacher; Véronique Dartois; Wai-Keung Chui; Colin J Jackson; Thomas Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.